Erwin Le Scolan
CytomX Therapeutics, South San Francisco, USA
Dr. Le Scolan has over 15 years of research experience in immuno-oncology. He joined CytomX in 2017 as a Scientist in Cancer Immunology. Dr. Le Scolan initiated and is currently leading CytomX’s conditionally active cytokine therapeutics program. Prior to CytomX, Dr. Le Scolan worked at Oncomed, where he supported multiple preclinical and clinical IO programs, and at Nodality, where he helped to develop a flow cytometry platform for preclinical and clinical IO research. Dr. Le Scolan began his career at Genentech where he supported the development of atezolizumab. Dr. Le Scolan received his Ph.D. in Virology from the University Denis Diderot (Paris). His doctoral work focused on the role of the transcriptional factor Spi1-/Pu1 in hematopoietic malignancies. He also performed post-doctoral work at UC Berkeley to study the role of TGF beta in immune cells and cancer.